520 related articles for article (PubMed ID: 21281410)
1. Treating disordered speech and voice in Parkinson's disease online: a randomized controlled non-inferiority trial.
Constantinescu G; Theodoros D; Russell T; Ward E; Wilson S; Wootton R
Int J Lang Commun Disord; 2011; 46(1):1-16. PubMed ID: 21281410
[TBL] [Abstract][Full Text] [Related]
2. Assessing disordered speech and voice in Parkinson's disease: a telerehabilitation application.
Constantinescu G; Theodoros D; Russell T; Ward E; Wilson S; Wootton R
Int J Lang Commun Disord; 2010; 45(6):630-44. PubMed ID: 20102257
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness of Lee Silverman Voice Treatment therapy issued interactively through an iPad device: A non-inferiority study.
Griffin M; Bentley J; Shanks J; Wood C
J Telemed Telecare; 2018 Apr; 24(3):209-215. PubMed ID: 28147896
[TBL] [Abstract][Full Text] [Related]
4. Innovative technology for the assisted delivery of intensive voice treatment (LSVT®LOUD) for Parkinson disease.
Halpern AE; Ramig LO; Matos CE; Petska-Cable JA; Spielman JL; Pogoda JM; Gilley PM; Sapir S; Bennett JK; McFarland DH
Am J Speech Lang Pathol; 2012 Nov; 21(4):354-67. PubMed ID: 23071195
[TBL] [Abstract][Full Text] [Related]
5. Effects of an extended version of the lee silverman voice treatment on voice and speech in Parkinson's disease.
Spielman J; Ramig LO; Mahler L; Halpern A; Gavin WJ
Am J Speech Lang Pathol; 2007 May; 16(2):95-107. PubMed ID: 17456888
[TBL] [Abstract][Full Text] [Related]
6. Lee Silverman Voice Treatment for people with Parkinson's: audit of outcomes in a routine clinic.
Wight S; Miller N
Int J Lang Commun Disord; 2015; 50(2):215-25. PubMed ID: 25469736
[TBL] [Abstract][Full Text] [Related]
7. Delivering the Lee Silverman Voice Treatment (LSVT) by web camera: a feasibility study.
Howell S; Tripoliti E; Pring T
Int J Lang Commun Disord; 2009; 44(3):287-300. PubMed ID: 18821113
[TBL] [Abstract][Full Text] [Related]
8. Intensive voice treatment (LSVT) for patients with Parkinson's disease: a 2 year follow up.
Ramig LO; Sapir S; Countryman S; Pawlas AA; O'Brien C; Hoehn M; Thompson LL
J Neurol Neurosurg Psychiatry; 2001 Oct; 71(4):493-8. PubMed ID: 11561033
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of Lee Silverman Voice Treatment on daily voice use in Parkinson's disease as measured with a portable voice accumulator.
Körner Gustafsson J; Södersten M; Ternström S; Schalling E
Logoped Phoniatr Vocol; 2019 Oct; 44(3):124-133. PubMed ID: 29447488
[TBL] [Abstract][Full Text] [Related]
10. Home-based speech treatment for Parkinson's disease delivered remotely: a case report.
Constantinescu GA; Theodoros DG; Russell TG; Ward EC; Wilson SJ; Wootton R
J Telemed Telecare; 2010; 16(2):100-4. PubMed ID: 20008051
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Quality of Life Outcomes of Speech Treatment for Parkinson's Disease Delivered to the Home Via Telerehabilitation: A Noninferiority Randomized Controlled Trial.
Theodoros DG; Hill AJ; Russell TG
Am J Speech Lang Pathol; 2016 May; 25(2):214-32. PubMed ID: 27145396
[TBL] [Abstract][Full Text] [Related]
12. Delivering group speech maintenance therapy via telerehabilitation to people with Parkinson's disease: A pilot study.
Quinn R; Park S; Theodoros D; Hill AJ
Int J Speech Lang Pathol; 2019 Aug; 21(4):385-394. PubMed ID: 29879854
[No Abstract] [Full Text] [Related]
13. The Lee Silverman Voice Treatment (LSVT®) speech therapy in progressive supranuclear palsy.
Sale P; Castiglioni D; De Pandis MF; Torti M; Dall'armi V; Radicati FG; Stocchi F
Eur J Phys Rehabil Med; 2015 Oct; 51(5):569-74. PubMed ID: 26138088
[TBL] [Abstract][Full Text] [Related]
14. A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease: a study protocol for a randomised controlled trial.
Sackley CM; Rick C; Au P; Brady MC; Beaton G; Burton C; Caulfield M; Dickson S; Dowling F; Hughes M; Ives N; Jowett S; Masterson-Algar P; Nicoll A; Patel S; Smith CH; Woolley R; Clarke CE;
Trials; 2020 May; 21(1):436. PubMed ID: 32460885
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Lee Silverman Voice Treatment (LSVT) on hypernasality in non-progressive dysarthria: the need for further research.
Wenke RJ; Theodoros D; Cornwell P
Int J Lang Commun Disord; 2010; 45(1):31-46. PubMed ID: 19565392
[TBL] [Abstract][Full Text] [Related]
16. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on ataxic dysarthria: a case study.
Sapir S; Spielman J; Ramig LO; Hinds SL; Countryman S; Fox C; Story B
Am J Speech Lang Pathol; 2003 Nov; 12(4):387-99. PubMed ID: 14658991
[TBL] [Abstract][Full Text] [Related]
17. Impact of the LSVT on vowel articulation and coarticulation in Parkinson's disease.
Sauvageau VM; Roy JP; Langlois M; Macoir J
Clin Linguist Phon; 2015 Jun; 29(6):424-40. PubMed ID: 25688915
[TBL] [Abstract][Full Text] [Related]
18. Changes to articulation following LSVT(R) and traditional dysarthria therapy in non-progressive dysarthria.
Wenke RJ; Cornwell P; Theodoros DG
Int J Speech Lang Pathol; 2010 Jun; 12(3):203-20. PubMed ID: 20433339
[TBL] [Abstract][Full Text] [Related]
19. Spectral/Cepstral Analyses of Phonation in Parkinson's Disease before and after Voice Treatment: A Preliminary Study.
Alharbi GG; Cannito MP; Buder EH; Awan SN
Folia Phoniatr Logop; 2019; 71(5-6):275-285. PubMed ID: 31117110
[TBL] [Abstract][Full Text] [Related]
20. The short- and long-term effectiveness of the LSVT for dysarthria following TBI and stroke.
Wenke RJ; Theodoros D; Cornwell P
Brain Inj; 2008 Apr; 22(4):339-52. PubMed ID: 18365848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
